Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • TG Therapeutics, Inc. (TGTX) Initiates Clinical Trial To Evaluate TG-1101, Lenalidomide Combination 0 comments
    Dec 7, 2012 6:03 PM | about stocks: TGTX

    Clinical-stage biopharm company TG Therapeutics today announced that it has initiated a phase I/II trial to evaluate the safety, tolerability, and efficacy of TG-1101, the company's novel third-generation anti-CD20 monoclonal antibody, in combination with lenalidomide (Revlimid®) for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy.

    This 30-patient multi-center trial is TG Therapeutics' second clinical trial of TG-1101 in North America; the company in September began enrollment of its on-going phase I/II trial with single agent TG-1101 in patients with Non-Hodgkin's Lymphoma (NHL).

    TG-1101 has displayed high single agent activity in a phase I/II clinical trial in patients with relapsed Chronic Lymphocytic Leukemia (CLL), and has been granted orphan status in Europe and in the USA for B-cell CLL.

    "We are very excited to announce the launch of our second clinical trial this year for TG-1101, now in combination with lenalidomide, targeting patients with advanced B-cell lymphoid malignancies, including CLL," Michael S. Weiss, executive chairman and interim CEO, stated in the press release.

    Weiss noted that it's a common belief among lymphoma experts that the combination of anti-CD20 therapy with lenalidomide has the potential to significantly impact the treatment model for patients with B-cell malignancies.

    "With a demonstrated ability to induce significantly greater ADCC activity over rituximab, TG-1101 is uniquely positioned to take advantage of the NK-cell activating properties exhibited by lenalidomide; providing a strong biological rationale for clinically meaningful synergy in the combination of these two agents," Weiss concluded.

    For more information visit www.tgtherapeutics.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: TGTX
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.